Discussion
VAGINA
In this study, there was no significant difference in BV cure rates between the probiotic and control groups at day 14, day 30, and day 90, suggesting a 30-day oral administration of The inability of the orally administered probiotic strains to reach or colonize the vagina may be the reason of the treatment failure in BV. Similarly, Husain et al. showed that the colonization rate of the intervention strains and the diversity of the vaginal microbiome did not differ between the probiotic and control groups (In this study, there was no difference in the relative abundance of We found that The abundance of key bacteria in the vagina influences whether BV can be cured in the long term (This study has some limitations. In terms of the clinical trial design, the participants completed their trials when diagnosed with BV, and there was no continuous follow-up for these patients. We were unable to provide a comprehensive description of the microbiome dynamics of BV treatment failure. Regarding bioinformatics analysis techniques, the relative abundance at the species level was insufficient to accurately calculate the number of intervention probiotic strains in the samples. In addition, the relatively small sample size is also one of the limitations of this study. Finally, future microbiome studies on probiotic interventions to assist in treating BV need to be supported by larger sample sizes and strain-level annotation techniques with higher resolution.